BACOP/BACODP交替联合化疗方案治疗非霍奇金淋巴瘤疗效分析

Analysis of the efficacy of alternate use of BACOP and BACODP for the treatment of non-Hodgkin's lym-phoma

目的探讨BACOP/BACODP交替联合化疗方案治疗非霍奇金淋巴瘤(NHL)的疗效与毒副反应。方法本组患者均应用BACOP/BACODP交替联合化疗方案治疗。化疗后残留病灶行局部放疗。结果完全缓解率为69.6％,总有效率为91.2％,1、3、5年生存率分别为70.5％、65.6％和62.7％。初治患者完全缓解率为73.8％,1、3、5年生存率分别为72.6％、68.6％和66.90%;复治患者完全缓解率为45.6％,1、3、5年生存率分别为57.5％、47.9％和38.3％。毒副反应均可耐受。结论BACOP/BACODP交替联合化疗方案有助于减少耐药细胞株产生,从而提高完全缓解率和远期生存率,且毒副反应可以耐受。

Objective To study the efficacy and toxicity of the alternate use of BACOP and BACODP for the treatment of non-Hodgkin's lymphoma. Methods 148 patients with histologically advanced non-Hodgkin's lymphoma were treated with BACOP /BACODP alternate regimen. Patients with residual lesions after chemotherapy received radiotherapy of involved field. 32 patients received radiotherapy. Results Out of 148 patients, CR was 69.6%, the total response rate was 91.3% and 1,3 and 5 year survival rates were 70.5% ,65.6% and 62.7% respectively.Among patients receiving chemotherapy, CR was 73.5%, and 1,3 and 5 year survival rates were 72.6% ,68.6% and 66.9% respectively. Among patients with relapse,CR was 45.6% , and 1,3 and 5 year survival rates were 57.5% ,47.9% and 38.3% respectively. Toxicity was well tolerated.Conclusion Alternate use of BACOP and BACODP regimens can reduce the production of drug-resistant cell strains and enhance CR rate and long-term survival rate. Their toxicity was tolerable.